Aeterna Zentaris Gmbh

Centre National De La Recherche Scientifique

University of Montpellier I

University of Montpellier Ii

Æterna Zentaris Gmbh

Gilbert Mueller

Matthias Gerlach

Eckhard Guenther

Tilmann Schuster

Michael Teifel

Emmanuel Polymeropoulos

Eckhard Günther

Irene Seipelt

Lars Blumenstein

Jean Martinez

Klaus Paulini

Peter Schmidt

Jean-Alain Fehrentz

Herbert Sindermann

Babette Aicher

Anne-Laure Blayo

Nicola Ammer

Pascal Marchand

Julien Defaux

Richard Sachse

The present invention provides new pyridopyrazine compounds of Formula (I) which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans. 

Pyridopyrazine derivatives and their use

The invention provides new pyridopyrazine compounds according to formula (I) 

Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors

The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and/or long term regulation of energy balance, short-, medium-, and/or long term regulation (stimulation and/or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and/or obesity, body weight gain and/or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors

The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine/threonine kinases and for the treatment of malignant or benign tumors and other disorders based on pathological cell proliferation, such as, for example, restenosis, psoriasis, arteriosclerosis and cirrhosis of the liver.

Naphthyridine derivatives and the use thereof as kinase inhibitors

Growing community of inventors

Frankfurt am Main, Germany

Gilbert Mueller